2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1469

Treatment Paradigms in Real-World Practice: Biologic Agent Use Prior to and after Discontinuation of Abatacept
Abstract Number: 1470

Impact of Anti-Drug Antibody and Injection Site Reaction on Efficacy: 24-Week Results from a Phase III Study Comparing SB4 (etanercept biosimilar) with Reference Etanercept in Patients with Rheumatoid Arthritis
Abstract Number: 1471

Flare Incidence and Predictive Factors in a Population of Patients with Rheumatoid Arthritis Under Optimised Treatment with Adalimumab and Infliximab
Abstract Number: 1472

Body Mass Index Does Not Affect Response to Rituximab in Patients with Rheumatoid Arthritis: Results from Turkbio Registry
Abstract Number: 1473

Golimumab Improves Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): Interim Results from a Non-Interventional Trial in Germany
Abstract Number: 1474

A Higher DAS28P, the Subjective Proportion of the DAS28, Predicts a Favorable Response to Abatacept in Rheumatoid Arthritis
Abstract Number: 1475

Collection of Anti-Rheumatic Medication Data from Both Patients and Rheumatologists Shows Strong Agreement in a Real World Clinical Cohort
Abstract Number: 1476

Effect of Treat-to-Target Tocilizumab- and Methotrexate-Based Strategies on Health-Related Quality of Life in Newly Diagnosed Rheumatoid Arthritis Patients: Results of the U-Act-Early Trial
Abstract Number: 1477

Patient-Reported Outcomes As Independent Measures of Treatment Success with Sirukumab, an Anti-IL6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis: Post-Hoc Analysis of 2 Placebo-Controlled Phase 3 Trials
Abstract Number: 1478

Inadequate Clinical Response to Sirukumab, an Anti-IL-6 Monoclonal Antibody, Can be Predicted after a Single Dose of Treatment in Patients with Rheumatoid Arthritis
Abstract Number: 1479

Difference in Clinical Presentation between Female and Male Patients with Primary Sjogren’s Syndrome at Diagnosis and in Long-Term Follow-up
Abstract Number: 1480

Risk of Ischemic Stroke in Sjögren’s Syndrome Patients: A Systematic Review and Meta-Analysis
Abstract Number: 1481

Risk of Ischemic Heart Disease in Sjögren’s Syndrome Patients: A Systematic Review and Meta-Analysis of Observational Studies
Abstract Number: 1482

Preliminary Population-Based Incidence and Prevalence Estimates of Primary Sjogren’s Syndrome from the Manhattan Lupus Surveillance Program
Abstract Number: 1483

Incidence of Cancer in a Cohort of Patients with Primary Sjögren Syndrome

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].